Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000950170-25-111753
Filing Date
2025-08-27
Accepted
2025-08-27 17:42:28
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 16787
  Complete submission text file 0000950170-25-111753.txt   18702
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Subject) CIK: 0001693011 (see all company filings)

EIN.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-91586 | Film No.: 251266666
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 501 SECOND STREET, SUITE 200 SAN FRANCISCO CA 94107
Business Address 501 SECOND STREET, SUITE 200 SAN FRANCISCO CA 94107 (345) 949 1040
Pivotal bioVenture Partners Fund I, L.P. (Filed by) CIK: 0001695076 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 0331
Type: SCHEDULE 13D/A